Impact of beta-blockers on prognostic outcomes in solid cancers: a systematic review and meta-analysis.
Sule Eraslan, Emine Ceren Ayhan, Michael Tvilling Madsen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of beta-blocker use on survival outcomes in patients with solid cancers, analyzing data from 603,827 patients across 84 studies. The findings indicate that beta-blocker use is associated with improved overall survival (HR = 0.88) and progression-free survival (HR = 0.82), particularly in gastrointestinal, lung, and skin cancers.
Key findings
- Beta-blocker use was linked to improved overall survival (HR = 0.88, 95% CI = 0.80 to 0.96).
- Progression-free survival also improved with beta-blocker use (HR = 0.82, 95% CI = 0.69 to 0.97).
- The most significant overall survival benefits were seen in gastrointestinal (HR = 0.84), lung (HR = 0.84), and skin cancers (HR = 0.81).
Why it matters
The potential for beta-blockers to improve survival outcomes in solid cancer patients suggests a need for further investigation into their role in oncology, which could lead to enhanced treatment strategies and patient management.
What to keep in mind
The majority of included studies were observational, and there was significant heterogeneity in the findings.